Literature DB >> 32180586

Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.

Meijing Wu1, Yue Sun1, Jing Wu1, Guoyan Liu1.   

Abstract

BACKGROUND High-grade serous ovarian cancer (HGSOC) is the most malignant gynecologic tumor. This study reveals biomarkers related to HGSOC incidence and progression using the bioinformatics method. MATERIAL AND METHODS Five gene expression profiles were downloaded from GEO. Differentially-expressed genes (DEGs) in HGSOC and normal ovarian tissue samples were screened using limma and the function of DEGs was annotated by KEGG and GO analysis using clusterProfiler. A co-expression network utilizing the WGCNA package was established to define several hub genes from the key module. Furthermore, survival analysis was performed, followed by expression validation with datasets from TCGA and GTEx. Finally, we used single-gene GSEA to detect the function of prognostic hub genes. RESULTS Out of the 1874 DEGs detected from 114 HGSOC versus 49 normal tissue samples, 956 were upregulated and 919 were downregulated. The functional annotation indicated that upregulated DEGs were mostly enriched in cell cycle, whereas the downregulated DEGs were enriched in the MAPK or Ras signaling pathway. Two modules significantly associated with HGSOC were excavated through WGCNA. After survival analysis and expression validation of hub genes, we found that 2 upregulated genes (MAD2L1 and PKD2) and 3 downregulated genes (DOCK5, FANCD2 and TBRG1) were positively correlated with HGSOC prognosis. GSEA for single-hub genes revealed that MAD2L1 and PKD2 were associated with proliferation, while DOCK5, FANCD2, and TBRG1 were associated with immune response. CONCLUSIONS We found that FANCD2, PKD2, TBRG1, and DOCK5 had prognostic value and could be used as potential biomarkers for HGSOC treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32180586      PMCID: PMC7101203          DOI: 10.12659/MSM.922107

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Ovarian cancer has a high mortality rate, which ranks first among gynecologic malignant tumors. Most deaths (70%) of patients presented with advanced-staged, high-grade serous ovarian cancer (HGSOC) due to the lack of specific symptoms at the early stage [1]. Therefore, it is of great significance to study the potential prognostic biomarkers related to the development of HGSOC. In recent years, bioinformatics-assisted analyses of expression profile have been widely used to detect the biomarkers of human diseases [2]. Weighted gene co-expression network analysis (WGCNA) is a biological approach to determine highly synergistic gene sets and to identify the association between gene modules and phenotype of samples [3]. WGCNA has been comprehensively utilized in multiple cancer-associated studies to determine hub genes that could be associated with respective traits, such as pancreatic carcinoma [4], colon cancer [5], and ovarian cancer [6-10]. However, few previous studies have focused on HGSOC. To identify potential biomarkers for specific diagnosis and therapy targets in HGSOC, WGCNA was performed to discover the hub genes that play an essential role in the development of HGSOC.

Material and Methods

Data collection

Five gene expression profiles were downloaded from the Gene Expression Omnibus (GEO) (). Datasets GSE18520 [11], GSE27651 [12], GSE54388 [13], GSE10971 [14] and GSE14001 [15] are listed in Supplementary Table 1, with a sample size of 114 for HGSOC and 49 normal tissue samples. All samples were processed using the Affymetrix human genome U133 plus 2.0 array. Genomic and clinical data were obtained from The Cancer Genome Atlas (TCGA) () and GTEx () [16] using the TCGAbiolinks package (Version 2.14.0; ) [17]. The RNA expression profiles were sampled from 363 high-grade serous ovarian cancer and 108 normal tissues.

Research design and data preprocessing

The research design is shown in a flowchart (Figure 1). The raw data from 5 datasets were chosen for integrated analysis using the affy package (Version 3.8; ) [18]. The batch effect of datasets was removed using the SVA package (Version 3.8; ) with its combat function (Supplementary Figure 1) [19].
Figure 1

Flow diagram of this study.

Differential gene expression analysis

We detected the DEGs between HGSOC and normal ovarian tissue samples using the limma package (Version 3.30.0; ) [20]. A false discovery rate (FDR) <0.05 and |log2FC|>1 were set as the criteria value. The expression intensity and direction of DEGs were represented using the pheatmap package (Version 1.0.12, ).

Function enrichment analyses

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of DEGs were conducted using the clusterProfiler package (Version 6.8; ) [21] to predict their underlying molecular functions. A p value of <0.05 was considered statistically significant.

Weighted gene co-expression network analysis (WGCNA)

We utilized the WGCNA package (Version 1.67; ) to construct a co-expression network for DEGs. To identify key modules, soft-thresholding power was set as β=9 (scale-free R2=0.84), and cut height was set as 0.25 (Supplementary Figure 2). We then explored the biological function of the modules that had the highest correlation with traits through GO and KEGG pathway analyses, and hub genes in a module were selected with |MM|>0.85 and |GS|>0.3.

Survival analysis and expression validation of hub genes

Survival analysis was performed for hub genes using the survival package (Version 2.43.3; ) and survminer package (Version 0.4.3; ). The Kaplan-Meier curves were plotted by the expression profiles from TCGA, which were divided into 2 groups based on a certain gene’s cutoff value as determined by survminer. The hub gene expression levels between HGSOC and normal tissue samples were also validated.

Gene set enrichment analysis (GSEA)

GSEA analysis of each hub gene with the TCGA-OV dataset was performed. The HGSOC samples (n=363) were divided into 2 groups according to the median expression value of each hub gene (high vs. low). A p value of <0.05 was considered as statistically significant. The “h.all.v6.2.entrez.gmt” were selected as reference gene sets, which were downloaded from the Molecular Signature Database (MSigDB, ).

Results

Differential expression analysis

We screened 1874 DEGs, including 919 downregulated and 956 upregulated genes, between HGSOC samples and normal tissue samples. The expression changes of DEGs were represented by a heatmap (Supplementary Figure 3), which showed that the samples were divided into 2 clusters.

Function enrichment for DEGs

The potential biological functions of the upregulated and downregulated differentially-expressed genes were annotated by clusterProfiler R package. The KEGG pathway analysis revealed that the upregulated genes were mainly involved in regulation of cell cycle, DNA replication, and biosynthesis of amino acids, while the downregulated genes were mainly linked to the Ras signaling pathway, complement and coagulation cascades, and the MAPK and JAK-STAT signaling pathways (Figure 2 and Supplementary Table 2). Furthermore, we performed GO enrichment analysis, the biological progress of which was in line with the KEGG enrichment results. Chromosome segregation and mitotic nuclear division were indicated for the upregulated genes, while morphogenesis of an epithelium and collagen-containing extracellular matrix were indicated for the downregulated genes (Figure 3 and Supplementary Table 3).
Figure 2

The KEGG pathway enrichment analysis of differently-expressed genes. (A) KEGG pathways enrichment for upregulated genes. (B) KEGG pathways enrichment for downregulated genes.

Figure 3

The GO enrichment analysis of differently-expressed genes. (A) GO enrichment analysis of upregulated genes. (B) GO enrichment analysis of downregulated genes.

Co-expression modules construction

To construct co-expression modules and find the key modules related to HGSOC, the expression profiles of 1874 DEGs were assessed with the WGCNA package. Hierarchical clustering analysis is presented in Figure 4A. Then, the highly related genes were put into modules. The MED threshold was set as 0.25, and 6 modules were excavated (Figure 4B). The genes that did not belong to any module were collected in the gray module, and were not used in any subsequent analysis. The other 5 modules are shown in blue, turquoise, yellow, brown, and green, respectively (Figure 4C). Among the 5 modules, the turquoise and blue modules had remarkable relevance for tumor progression (Figure 4C, 4D).
Figure 4

Co-expression modules construction and selection. (A) Samples clustering and trait heatmap of datasets from GEO according to the DEGs expression between HGSOC and normal tissue samples. (B) Dendrogram of all DEGs were clustered with dissimilarity according to topological overlap (1-TOM). (C) associations between modules and traits. In each cell, the upper number is the correlation coefficient of the module in the trait, and the lower number is the p value. Among them, the turquoise and blue modules were the most correlative with normal and cancer traits. (D) Distribution of average gene significance in the modules correlated with HGSOC. TOM – topological overlap matrix.

Moreover, intramodular analysis for GS and MM resulted in the identification of genes in the turquoise module, which were negatively correlated with HGSOC (correlation=0.75 and p<9.5e–155) and genes in the blue module revealed a highly positive correlation with HGSOC (correlation=0.7 and p<3.2e–118), as shown in Figure 5A.
Figure 5

Select hub genes in significant co-expression modules. (A) The scatter plot of gene significance (GS) versus module membership (MM) in the blue module and turquoise module. (B) The heatmap presents the TOM among all genes. Colors beneath and right of the dendrograms explain the color-coding for each module. The more saturated yellow and red indicates a high co-expression inter-connectedness in the heatmap (C). Clustering of module eigengenes and the heatmap of the adjacencies.

The heatmap was plotted to show all genes (Figure 5B). To quantify co-expression similarity of the 5 modules, we calculated the connectivity of eigengenes. Positively correlated eigengenes were grouped together, with 2 of 5 modules were classified into one cluster and 3 into another. The heatmap of the adjacencies is also presented (Figure 5C). There were 76 hub genes from the turquoise module and 76 hub genes from the blue module selected, with a threshold module membership (MM) >0.85 and gene significance (GS) >0.3 (Supplementary Table 4). The turquoise and blue modules were analyzed by STRING database, with a combined score >0.7 and were visualized by Cytoscape software (Figure 6).
Figure 6

Protein–Protein Interaction (PPI) network of genes in 2 modules. (A) The genes in blue module. (B) The genes in turquoise module. The color presents the fold change (upregulated genes are red, downregulated genes are green).

To investigate the potential functions of the genes within the 2 modules (turquoise and blue), we performed GO and KEGG pathway analyses, and showed the most significant GO terms and KEGG pathways in Figure 7. This analysis revealed that genes in the blue module were mainly enriched in cell cycle and DNA replication, while genes in the turquoise module played their roles in different signal pathways.
Figure 7

GO and KEGG pathway analysis of the 2 modules. (A) KEGG pathway analysis of blue module; (B) KEGG pathway analysis of turquoise module; (C) GO analysis of blue module; (D) GO analysis of turquoise module. GO analysis includes biological process (BP), cellular component (CC), and molecular function (MF). The count represents the number of genes in each pathway and dot size corresponds to “count”.

Validation of hub genes

Analyzing the results of WGCNA, we found that the turquoise and blue modules had the highest association with HGSOC. Accordingly, we hypothesized that the genes in the turquoise module might act as tumor suppressors and genes in the blue module might act as tumor promoters. Survival analyses were performed among the 152 hub genes selected from the 2 modules. We found that MAD2L1 and FANCD2 in the blue module and PKD2, TBRG1, and DOCK5 in the turquoise module were consistent with our speculation. Survival curves showed that higher expression of MAD2L1 and FANCD2 was significantly associated with poor prognosis of patients, as was the lower expression of PKD2, TBRG1, and DOCK5 (Figure 8). Finally, we used gene profiles downloaded from TCGA and GTEx to validate the expression of these genes, and the results were similar to the expression exhibited by GEO (Figure 9).
Figure 8

Kaplan-Meier analysis of (A) MAD2L1, (B) PKD2, (C) DOCK5, (D) FANCD2, and (E) TBRG1 by comparing the higher (red) and lower (green) expressions with overall survival outcomes for patients with HGSOC.

Figure 9

Validation of hub gene expressions in the TCGA and GTEx datasets. (A) MAD2L1, (B) PKD2, (C) DOCK5, (D) FANCD2, and (E) TBRG1 gene expression differences between HGSOC and normal tissues.

Potential function of hub genes through GSEA

To better understand the potential biological functions of MAD2L1, FANCD2, PKD2, TBRG1, and DOCK5 in HGSOC, we performed GSEA based on the TCGA-OV dataset. As shown in Figure 10, genes in higher-expression groups of MAD2L1 and FANCD2 were all involved in “E2F TARGETS” and “G2M CHECKPOINT” of the cell cycle, which indicated that these 2 upregulated genes are closely associated with tumor proliferation, whereas “TNFA SIGNALING VIA NFKB”, “interferon gamma RESPONSE” and “inflammatory response” were enriched in the PKD2, TBRG1, and DOCK5 high-expression groups, which indicated these downregulated genes are involved in immune response (Supplementary Table 5).
Figure 10

Gene set enrichment analysis (GSEA) of hub genes in the TCGA-OV dataset. Three gene sets enriched in the high-expressed group of single-hub genes. (A) MAD2L1, (B) FANCD2, (C) PKD2, (D) TBRG1, and (E) DOCK5.

Discussion

With the purpose of identifying the molecular mechanism of HGSOC and to investigate potential biomarkers for better detection and therapy, we integrated the gene expression profiles of GSE54388, GSE27651, GSE10971, GSE18520, and GSE14001, which contained 114 samples of HGSOC tissue and 49 samples of normal tissue. We identified 1874 DEGs that were correlated with HGSOC, and the cutoff criteria were p<0.05 and |logFC|≥1. In KEGG analysis, the upregulated genes were predominantly involved in cell cycle and DNA replication, while the downregulated genes were highly involved in Ras signaling, complement and coagulation cascades, and MAPK signaling pathways. The GO analysis supported the previous enrichment analysis, which both help to understand the role of DEGs in HGSOC. WGCNA analysis was used to select co-expression modules related to the development of HGSOC, and 2 modules (blue and turquoise) were found to have the highest correlation with HGSOC. We showed the Protein–Protein Interactions (PPI) network and also performed GO and KEGG analyses for genes in the 2 modules. The results indicated that genes in the blue module were enriched in cell cycle and DNA replication, while genes in the turquoise module were involved in different signaling pathways. After filtering with MM and GS value, we detected 152 hub genes from the 2 modules. Five genes – MAD2L1 and FANCD2 in the blue module and PKD2, TBRG1, and DOCK5 in the turquoise module – were excavated after survival analysis and expression validation with datasets downloaded from TCGA, and were found to have prognostic value for HGSOC. Among these 5 hub genes, MAD2L1 and FANCD2 are associated with ovarian cancer. As a component of the mitotic checkpoint, high levels of MAD2L1 are related to increased cellular proliferation, migration, and metastasis, which can lead to shorter survival in various cancers [22-26]. However, in ovarian cancer, the role of MAD2L1 did not agree with previous findings that patients with lower MAD2L1 levels were less sensitive to paclitaxel and had shorter progression-free survival (PFS) and overall survival (OS) [27,28]. This discrepancy might have been caused by our analysis, ignoring the mutations of p53 and BRCA1, which are known regulators of MAD2L1 and are commonly mutated in HGSOC [29,30]. High FANCD2 levels have been shown to be associated with poor prognosis in many types of cancer [31-35], as well as in ovarian cancer [36]. FANCD2 overexpression can stabilize the replication fork, and create BRCA1/2 mutant tumor resistance towards PARP1/2 inhibitor treatments [37]. The results indicated that FANCD2 expression can influence cancer sensitivity to PARP1/2 inhibitors and thus could be used as a potential target of therapy. To further explore the biological functions of the 5 selected hub genes, we conducted single-gene GSEA. “E2F TARGETS” and “G2M CHECKPOINT” were enriched in the high-expression groups of MAD2L1 and FANCD2, indicating their contribution to HGSOC proliferation. In the high-expression groups of PKD2, TBRG1, and DOCK5, immune-related signals, such as “TNFA SIGNALING VIA NFKB”, “INTERFERON GAMMA RESPONSE” and “INFLAMMATORY RESPONSE” were enriched, indicating the activity of immune response.

Conclusions

We identified several DEGs and meaningful gene modules in HGSOC. Four valuable hub genes (FANCD2, PKD2, TBRG1, and DOCK5) were strongly dysregulated in HGSOC tissues. GSEA further suggested that FANCD2 is associated with tumor proliferation, while PKD2, TBRG1, and DOCK5 influence immune response. More work is needed to fully reveal their individual contributions towards the pathogenesis of HGSOC and to validate their value as prognostic biomarkers. Limitations of this study include the lack of analysis for detailed clinical classification of HGSOC, such as grade, stage, lymph node metastasis, and prognosis. In future research, we will explore hub genes and their potential function based on this clinical information in detail. Characteristics of the included datasets. Samples clustering of 5 datasets after removing the batch effects. Soft-thresholding power determination in WGCNA. (A) Analysis of the scale-free fit index for different soft-thresholding powers. (B) Mean connectivity for various soft-thresholding powers. (C) Histogram of connectivity distribution when β=9. (D) Check scale-free topology when β=9. Heatmap of the top 200 DEGs based on the value of |logFC|. High or low expression is shown as a red or blue strip, respectively. The experimental group was labelled HGSOC, while the control group was named Nor. The KEGG enrichment analysis of genes. The GO enrichment analysis of genes. Hub genes in blue and turquoise module (|MM|>0.85 and |GS|>0.3). MM – module membership; GS – gene significance. The Gene Set Enrichment Analysis (GSEA) of hub genes.
Supplementary Table 1

Characteristics of the included datasets.

Dataset IDGPL IDHigh-grade serous ovarian carcinomaNormal ovarian surface epithelium
GSE18520GPL5705310
GSE27651GPL570226
GSE54388GPL570166
GSE10971GPL5701324
GSE14001GPL570103
Supplementary Table 2

The KEGG enrichment analysis of genes.

IDDescriptionp. adjustCountRegulation
hsa04110Cell cycle0.00063335up
hsa03030DNA replication0.01209314up
hsa01230Biosynthesis of amino acids0.02847812up
hsa04014Ras signaling pathway0.00750325down
hsa04610Complement and coagulation cascades0.00750314down
hsa04010MAPK signaling pathway0.00750329down
hsa04630JAK-STAT signaling pathway0.00750313down
hsa04728Dopaminergic synapse0.00750313down
hsa05032Morphine addiction0.00750313down
hsa04261Adrenergic signaling in cardiomyocytes0.01325112down
hsa05146Amoebiasis0.0321314down
Supplementary Table 3

The GO enrichment analysis of genes.

OntologyIDDescriptionp. adjustCountRegulation
BPGO: 0007059Chromosome segregation7.51E-3076up
BPGO: 0140014Mitotic nuclear division8.88E-2869up
BPGO: 0000280Nuclear division1.11E-2683up
BPGO: 0048285Organelle fission3.71E-2585up
BPGO: 0098813Nuclear chromosome segregation5.13E-2563up
CCGO: 0098687Chromosomal region1.26E-2674up
CCGO: 0000775Chromosome, centromeric region2.73E-2453up
CCGO: 0000793Condensed chromosome1.10E-2052up
CCGO: 0000779Condensed chromosome, centromeric region2.30E-1937up
CCGO: 0005819Spindle2.30E-1962up
MFGO: 0140097Catalytic activity, acting on DNA2.32E-0834up
MFGO: 0008094DNA-dependent ATPase activity1.57E-0519up
MFGO: 0016887ATPase activity0.00022647up
MFGO: 0043142Single-stranded DNA-dependent ATPase activity0.0003257up
MFGO: 0001077Proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific0.00032535up
BPGO: 0002009Morphogenesis of an epithelium9.98E-0753down
BPGO: 0016049Cell growth2.29E-0652down
BPGO: 0001822Kidney development6.68E-0635down
BPGO: 0072001Renal system development6.68E-0636down
BPGO: 0003002Regionalization6.68E-0640down
CCGO: 0062023Collagen-containing extracellular matrix1.22E-1149down
CCGO: 0031012Extracellular matrix1.29E-1059down
CCGO: 0042383Sarcolemma3.36E-0521down
CCGO: 0005604Basement membrane3.64E-0517down
CCGO: 0031252Cell leading edge0.00642234down
MFGO: 0005201Extracellular matrix structural constituent4.99E-0524down
MFGO: 0005539Glycosaminoglycan binding5.13E-0529down
MFGO: 1901681Sulfur compound binding6.67E-0530down
MFGO: 0008201Heparin binding0.00012923down
MFGO: 0005518Collagen binding0.00083613down
Supplementary Table 4

Hub genes in blue and turquoise module (|MM|>0.85 and |GS|>0.3).

Blue moduleTurquoise module
GeneMMGSGeneMMGS
CSE1L0.8851820.654936LRRN40.863969−0.76695
PCNA0.8532680.634531LINC011050.85413−0.83749
HNRNPAB0.8590020.665006DAB20.928442−0.84279
TOP2A0.8916790.822887CELF20.888927−0.77641
SMC40.9170930.806692LAMA40.850672−0.68463
MTHFD20.8774580.806098SPOCK10.867854−0.80181
PSRC10.8715280.788497PAPSS20.879786−0.72486
CKS1B0.9340630.787083DAPK10.899065−0.7982
MCM20.9225480.841694PROCR0.898493−0.7677
PCLAF0.8992580.817579PKD20.929768−0.75857
CRABP20.872720.877783GSDME0.91672−0.80166
CCNB20.8976720.848503IGFBP60.892364−0.79082
LSM40.8716550.664114THBD0.869457−0.80323
CDC200.8937280.758763KDR0.884189−0.74272
UBE2C0.8764990.834623FRY0.899738−0.80017
CDK10.8765490.8119GNG110.930805−0.75466
EZH20.8621780.795034ABCA80.944703−0.89654
MAD2L10.8892830.76929GPRASP10.899009−0.87775
PTTG10.8705740.824798GFPT20.866683−0.7817
BUB1B0.8929620.819369RNASE40.903103−0.80729
DLGAP50.8770170.82571CALB20.897513−0.85688
ZWINT0.9227120.79987BCHE0.922752−0.81917
TRIP130.8843670.77344NPY1R0.882911−0.85536
RAD51AP10.8583950.802612GHR0.888245−0.71151
NDC800.867730.721595ECM20.850415−0.66158
CKS20.940520.829763ARHGAP60.869659−0.73929
KIF110.8852830.822206WNT2B0.877108−0.80996
NEK20.890350.839637PTGIS0.883089−0.79366
KIF230.8532230.7629LGALS20.85777−0.75854
FEN10.9095330.760884MAF0.898868−0.73781
TTK0.8948590.855031SYNE10.854181−0.8207
MELK0.9005540.813158PLPP10.920489−0.7545
STIL0.8679570.835405TCEAL20.877183−0.81491
SAC3D10.8748050.712282TBC1D2B0.862424−0.70643
HMGA10.8696410.806441PDE8B0.878248−0.91687
GINS10.8937050.7861ATP10D0.88824−0.74775
CENPF0.8800110.84842TFPI0.86169−0.75802
AURKA0.9142240.801243CHN20.855714−0.81706
EIF4G10.8699790.737708BICC10.864204−0.82881
NR2F60.8871030.752212DIXDC10.858203−0.8161
BUB10.9137640.809106DIRAS30.875531−0.8524
PUF600.8664610.739985OLFML10.886786−0.70603
TPX20.8627160.819783CSGALNACT10.90082−0.83324
RPL39L0.8574160.742065PDGFD0.866505−0.68393
EIF60.860570.671087RADX0.868631−0.84742
XPOT0.8575860.684634KLF20.894365−0.78132
SCRIB0.8673930.771012SMPD30.867973−0.78767
CCNA20.8685010.7858PPP1R3B0.85511−0.72434
CCNB10.9047170.755995OGN0.88218−0.80725
PRC10.8869140.802267ABI3BP0.872052−0.78816
MRPL150.8538470.663766ITLN10.884383−0.81818
NUSAP10.8670730.795277MGARP0.903375−0.8306
SLC52A20.8683920.803613ARHGAP180.918993−0.80114
TACC30.8751770.752928DDR20.852443−0.67497
KIF4A0.8711670.797892ANTXR20.858928−0.72284
CEP550.8507440.827425LIX1L0.878142−0.68937
DTL0.8652550.780689MCC0.870811−0.71797
KIF20A0.8884070.82511TBRG10.85824−0.79791
CENPU0.8639960.732426PTPN210.863405−0.7201
KIF150.8827330.786989CNRIP10.889837−0.80871
ECT20.9167320.831958PPM1K0.895422−0.86713
CDCA80.859160.797452MEDAG0.866729−0.84797
MCM40.9140840.813176LINC012790.857322−0.66728
RACGAP10.9189410.779139PLEKHH20.865982−0.76522
PSAT10.8540150.826163SLC30A40.904509−0.70542
UBE2T0.8509960.725215TCEAL30.856911−0.7193
SLC25A330.8689870.6974CDON0.869831−0.69303
CDCA30.8573040.797015TCEAL70.870405−0.84944
NUF20.919850.868254ERN10.880253−0.77167
RCC20.9095210.783731MUM1L10.899449−0.85402
FAM83D0.9013930.849648RNASEL0.872061−0.72795
POC1A0.8560440.816551DOCK50.893588−0.83622
DEPDC1B0.8542640.764695RBMS30.850965−0.82463
CENPL0.8573680.768059HAND2-AS10.858159−0.89488
KIF140.9029180.830047DTWD10.879321−0.75556
FANCD20.8900710.736399IFFO10.857298−0.73892

MM – module membership; GS – gene significance.

Supplementary Table 5

The Gene Set Enrichment Analysis (GSEA) of hub genes.

DescriptionsetSizeenrichmentScoreNESp.adjustcore_enrichment
MAD2L1ALLOGRAFT REJECTION1200.4387381.7617020.007716CDKN2A/NME1/GZMB/MMP9/CXCL9/CCL5/CXCL13/IL15/CCL11/EIF5A/TAP1/CCL13/GZMA/SRGN/IL2RG/CCL2/UBE2N/CCL7/HLA-DOB/CTSS/CCL4/B2M/CD3D/PRF1/CD2/LTB/TNF/SIT1/IL2RA/CD7/HLA-G/CD8A/CD3E/ST8SIA4/CD86/FCGR2B/IFNG/IL12A/CXCR3/LY86/CD8B/RIPK2/UBE2D1/TPD52/HLA-DQA1/MRPL3/CD80/WARS/CD79A/CCR1/LCK/HDAC9/IGSF6/BCL10/TRAT1/CAPG/CD3G/CD96/IL11/IL2RB/MAP4K1/KRT1
E2F TARGETS1050.8058463.1555880.007716MAD2L1/CDKN2A/BIRC5/CKS2/CKS1B/CCNE1/TK1/UBE2S/PTTG1/UBE2T/MYBL2/NME1/CCNB2/AURKB/PLK1/DEPDC1/KPNA2/CDC20/RRM2/CENPM/CDKN3/CDK1/PLK4/AURKA/PCNA/SNRPB/KIF2C/SPC25/TRIP13/JPT1/ASF1B/ORC6/H2AFX/TOP2A/MELK/RNASEH2A/TACC3/CDCA8/DLGAP5/KIF4A/DCTPP1/SPC24/RFC3/CENPE/HMMR/RAD51AP1/DIAPH3/STMN1/POP7/BUB1B/DCK/MTHFD2/RPA3/GINS1/SPAG5/RACGAP1/KIF22/GINS4/ DDX39A/DSCC1/CDC25A/KIF18B/RAN/E2F8/RFC2/TUBG1/SLBP/BRCA2/HMGB3/SUV39H1/CHEK1/PRIM2/GINS3/ESPL1/SMC4/MXD3
G2M CHECKPOINT1040.7596342.9758610.007716MAD2L1/CCNA2/UBE2C/BIRC5/CKS2/CKS1B/UBE2S/PTTG1/MYBL2/PBK/CCNB2/AURKB/PLK1/KPNA2/CDC20/CENPA/CDKN3/TTK/CDK1/PLK4/NEK2/AURKA/GINS2/KIF2C/JPT1/ORC6/H2AFX/CDC45/TOP2A/TROAP/TACC3/CDC6/SNRPD1/TPX2/KIF4A/NUSAP1/CENPE/HMMR/NDC80/STMN1/BUB1/EXO1/DTYMK/KIF23/TRAIP/PRC1/RACGAP1/KIF22/E2F1/DDX39A/CDC25A/POLQ/KIF15/FBXO5/RAD54L/KNL1/KIF11/BRCA2/HMGB3/E2F2/SUV39H1/CHEK1/CENPF/PRIM2/ESPL1/SMC4/ODC1/CCNF/STIL/SMC2/CDC7/MCM6/HIST1H2BK/EZH2/MCM2
FANCD2G2M CHECKPOINT1040.9010153.3696040.006028MYBL2/KIF15/TPX2/TOP2A/KIF2C/UBE2C/BIRC5/ESPL1/MAD2L1/HMMR/PBK/KIF4A/PLK1/TROAP/TTK/BUB1/CDC20/POLQ/ NUSAP1/RACGAP1/CCNB2/AURKB/CENPA/MKI67/CCNA2/KNL1/CDK1/TACC3/TRAIP/ PLK4/E2F2/CENPF/AURKA/KIF23/KIF11/ BRCA2/NEK2/CDC45/NDC80/EXO1/CDC25A/E2F1/CKS1B/CDC6/UBE2S/PRC1/KPNA2/RAD54L/CKS2/CENPE/SMC2/STIL/CCNF/LMNB1/CDKN3/PTTG1/STMN1/EZH2/ORC6/GINS2/CDC7/FBXO5/MCM2/ODC1/NSD2/H2AFX/KIF22/MCM6/INCENP/SMC4/CHEK1/DDX39A/KIF20B/BARD1/DTYMK/CHAF1A/SUV39H1
E2F TARGETS1050.8890413.342870.006028MYBL2/CDKN2A/DEPDC1/MELK/CCNE1/ASF1B/TOP2A/KIF2C/TRIP13/BIRC5/ESPL1/BUB1B/MAD2L1/HMMR/KIF4A/PLK1/CDC20/CIT/CDCA8/SPAG5/SPC24/RACGAP1/CCNB2/AURKB/RRM2/TK1/MKI67/KIF18B/DLGAP5/CDK1/TACC3/PLK4/GINS4/AURKA/BRCA2/E2F8/RFC3/DIAPH3/SPC25/CDC25A/CKS1B/TIMELESS/UBE2S/RAD51AP1/KPNA2/CKS2/CENPE/GINS1/LMNB1/CDKN3/PTTG1/STMN1/UBE2T/CENPM/EZH2/ORC6/ATAD2/MCM2/MCM4/NCAPD2/HELLS/RNASEH2A/PCNA/H2AFX/KIF22/MCM6/SMC4/CHEK1/DDX39A/BARD1/DSCC1/GINS3/TCF19/SUV39H1/RFC2/CSE1L/UNG/MSH2/SNRPB/PRIM2/HMGB3/RAN/DCLRE1B/JPT1/NME1/TUBG1/DCK/MTHFD2/DCTPP1/TUBB/PAICS/DEK/PA2G4/DONSON/SLBP
MITOTIC SPINDLE800.7989212.8885740.006028KIF15/TPX2/TOP2A/KIF2C/BIRC5/ESPL1/ KIF4A/PLK1/TTK/BUB1/ANLN/NUSAP1/RACGAP1/CCNB2/ECT2/DLGAP5/CDK1/CENPF/AURKA/KIF23/KIF11/BRCA2/NEK2/NDC80/PRC1/PIF1/CENPE/LMNB1/FBXO5/KIF22/INCENP/SMC4/KIF20B/CENPJ/SASS6
PKD2KRAS SIGNALING UP1180.6565112.2706590.004293MMP11/PRRX1/PLAU/TMEM158/ETV1/CFH/GFPT2/LIF/PLAT/SPARCL1/ADGRA2/ TMEM176A/MMP9/LAPTM5/ITGB2/PCSK1N/TMEM176B/RGS16/EPB41L3/ENG/NRP1/TNFAIP3/IL2RG/APOD/MALL/EPHB2/IKZF1/PLAUR/WNT7A/MAFB/TFPI/AKAP12/TRIB2/KLF4/CXCL10/SPP1/BMP2/C3AR1/SPON1/ ETV5/ADAMDEC1/LCP1/FCER1G/FLT4/GYPC/G0S2/TRAF1/DUSP6/CTSS/ADAM8/SOX9/PPP1R15A/MMD/IRF8
PKD2TNFA SIGNALING VIA NFKB1090.6967732.3958920.004293SERPINE1/PLAU/FOSB/KLF2/ICAM1/GFPT2/LIF/EGR1/SLC2A3/FOS/ZFP36/DUSP1/EGR2/TNFAIP6/NR4A1/GEM/OLR1/CCL5/NR4A3/EGR3/TNFAIP3/LDLR/TNFAIP2/GADD45B/PLAUR/PLEK/NFAT5/CDKN1A/CCL2/KDM6B/KLF4/CXCL1/CXCL10/BMP2/SIK1/IL6ST/ DUSP4/FOSL2/CCL4/CXCL11/IER3/G0S2/ TRAF1/JUNB/F3/CD44/PPP1R15A/SERPINB2/RHOB/NR4A2/KLF9/SGK1/PTGER4/IFIT2/B4GALT5/MAFF/IER5/CXCL6/ETS2/PER1/BCL6/TAP1/TNFRSF9/SMAD3/ID2/PLPP3/IL1B/PTX3/SLC2A6/RNF19B/BIRC3/IFIH1
INTERFERON GAMMA RESPONSE1070.6283082.1600280.004293C1S/CFH/CXCL9/ICAM1/C1R/XAF1/TNFAIP6/OAS2/IL2RB/LATS2/CCL5/CSF2RB/LCP2/ IFI44L/OAS3/HLA-DQA1/RSAD2/TNFAIP3/HLA-B/TNFAIP2/MX1/HELZ2/SLAMF7/ CDKN1A/CCL2/STAT1/CXCL10/FAS/EPSTI1/IFIT3/CD38/PIM1/TAPBP/CXCL11/SELP/CD74/WARS/ST8SIA4/IRF8/ST3GAL5/IFI44/LY6E/CD86/LGALS3BP/IFIT2/FCGR1A/OASL/EIF2AK2/MYD88/IFI30/CFB/TAP1/IFIT1/CMPK2/B2M/HLA-DRB1/PML/IFIH1/TXNIP/IFI27/HLA-G/ JAK2/TRIM14
TBRG1ALLOGRAFT REJECTION1200.4897081.9240570.008729IL18/THY1/LIF/CD74/HLA-DOA/HLA-DMA/HLA-DQA1/C2/HLA-DRA/LTB/IL2RG/FAS/ELF4/PRKCB/CD47/PRKCG/B2M/CD3E/LY75/ICAM1/INHBB/TAP1/TAPBP/IL2RB/HDAC9/CD2/IL16/CCL5/GZMA/FYB1/CD96/CD4/JAK2/CXCL9/IL15/STAB1/CD7/CCL4/ITGAL/HLA-DOB/IGSF6/IKBKB/HLA-G/ITGB2/LYN/TNF/IL12A/SPI1/PTPRC/CRTAM/CD8A/PRF1/CCL22/WAS/LCP2/CTSS/CD3D/FASLG/CXCR3
TNFA SIGNALING VIA NFKB1090.5495172.1281810.008729BIRC3/IL18/CCND1/FOS/FOSB/LIF/CCL20/GADD45B/EGR1/CEBPD/EDN1/JUNB/SGK1/CCNL1/NR4A1/NFAT5/ZFP36/F3/IRF1/KLF2/TNFAIP2/IFIT2/CLCF1/SMAD3/ETS2/DUSP1/ICAM1/TAP1/LAMB3/MAFF/SERPINB2/PLAU/TRIB1/EGR3/BTG2/CCL5/TRAF1/IL6ST/CCL4/BTG3/TRIP10/TNFAIP3/IER3/TIPARP/EGR2/BMP2/TNF
INTERFERON GAMMA RESPONSE1070.5247592.031160.008729CFB/XAF1/CD74/HLA-DMA/HLA-DQA1/IFITM3/HLA-DRB1/MX2/RTP4/PSMB8/IFI27/PSMB9/IRF1/IDO1/IFIT3/IFIT1/LY6E/FAS/TNFAIP2/ IFIT2/EPSTI1/B2M/ZBP1/TXNIP/ICAM1/TAP1/TAPBP/IL2RB/PML/TNFSF10/ITGB7/HLA-B/CCL5/CASP8/GZMA/SLC25A28/JAK2/C1R/CXCL9/IL15/NMI/SECTM1/MX1/HLA-G/TNFAIP3/UBE2L6/C1S/PARP12
DOCK5TNFA SIGNALING VIA NFKB1090.5584752.3194620.007567CD44/CCND1/FOSB/FOS/BIRC3/LAMB3/TNFAIP2/IL18/NFAT5/LDLR/EGR3/KLF2/EGR1/ZFP36/KLF9/BCL6/SIK1/SMAD3/DUSP1/ NR4A1/ETS2/IL6ST/SGK1/BTG2/CEBPD/GADD45B/DUSP4/PER1/KLF4/IRF1/EDN1/TRIP10/ICAM1/NR4A2/F3/TRAF1/SLC2A3/RHOB/FOSL2/IFIT2/STAT5A/CDKN1A/OLR1/KYNU/PLAU/LIF/TNFAIP3/CXCL1/MAFF/EGR2/JUNB/GFPT2/RIPK2/IL1B/RNF19B/F2RL1/ CXCL6/G0S2/PPP1R15A/PLEK/IER5/ICOSLG/TNFAIP8/TRIB1/MAP2K3
INFLAMMATORY RESPONSE1040.4655851.9167310.007567SLC7A2/CD82/GPR132/STAB1/IL18/LDLR/TNFSF15/TAPBP/P2RX7/CYBB/PTAFR/BTG2/CLEC5A/TPBG/SLC7A1/MET/AHR/RASGRP1/IL2RB/IRF1/SGMS2/EDN1/LYN/ICAM1/ GABBR1/F3/TNFSF10/ITGB8/C3AR1/APLNR/LCP2/CDKN1A/OLR1/AQP9/LIF/RGS16/CCL22/RGS1/SELE/RTP4/RIPK2/IL1B/ITGA5/CXCL6/PCDH7/CD14/CCR7/SLC11A2/ICOSLG
UV RESPONSE DN620.5845052.2107840.007567CELF2/MGLL/RUNX1/IRS1/DLC1/RBPMS/LDLR/MT1E/SYNE1/SMAD3/PTPN21/DUSP1/GCNT1/PTPRM/VLDLR/SIPA1L1/CAV1/SLC7A1/MET/FHL2/PDGFRB/RND3/EFEMP1/F3/NRP1/ ANXA2/APBB2/PRDM2/PPARG
  37 in total

1.  High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer.

Authors:  Jung-Woo Choi; Younghye Kim; Ju-Han Lee; Young-Sik Kim
Journal:  Virchows Arch       Date:  2013-08-31       Impact factor: 4.064

2.  Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.

Authors:  Hisateru Komatsu; Takaaki Masuda; Tomohiro Iguchi; Sho Nambara; Kuniaki Sato; Quingjang Hu; Hidenari Hirata; Shuhei Ito; Hidetoshi Eguchi; Keishi Sugimachi; Hidetoshi Eguchi; Yuichiro Doki; Masaki Mori; Koshi Mimori
Journal:  Anticancer Res       Date:  2017-03       Impact factor: 2.480

3.  Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.

Authors:  Emina Emilia Torlakovic; Robert Riddell; Diponkar Banerjee; Hala El-Zimaity; Dragana Pilavdzic; Peter Dawe; Anthony Magliocco; Penny Barnes; Richard Berendt; Donald Cook; Blake Gilks; Gaynor Williams; Bayardo Perez-Ordonez; Bret Wehrli; Paul E Swanson; Christopher N Otis; Søren Nielsen; Mogens Vyberg; Jagdish Butany
Journal:  Am J Clin Pathol       Date:  2010-03       Impact factor: 2.493

4.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Authors:  Samuel C Mok; Tomas Bonome; Vinod Vathipadiekal; Aaron Bell; Michael E Johnson; Kwong-kwok Wong; Dong-Choon Park; Ke Hao; Daniel K P Yip; Howard Donninger; Laurent Ozbun; Goli Samimi; John Brady; Mike Randonovich; Cindy A Pise-Masison; J Carl Barrett; Wing H Wong; William R Welch; Ross S Berkowitz; Michael J Birrer
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

5.  FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.

Authors:  Zeina Kais; Beatrice Rondinelli; Amie Holmes; Colin O'Leary; David Kozono; Alan D D'Andrea; Raphael Ceccaldi
Journal:  Cell Rep       Date:  2016-06-02       Impact factor: 9.423

6.  A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project.

Authors:  Latarsha J Carithers; Kristin Ardlie; Mary Barcus; Philip A Branton; Angela Britton; Stephen A Buia; Carolyn C Compton; David S DeLuca; Joanne Peter-Demchok; Ellen T Gelfand; Ping Guan; Greg E Korzeniewski; Nicole C Lockhart; Chana A Rabiner; Abhi K Rao; Karna L Robinson; Nancy V Roche; Sherilyn J Sawyer; Ayellet V Segrè; Charles E Shive; Anna M Smith; Leslie H Sobin; Anita H Undale; Kimberly M Valentino; Jim Vaught; Taylor R Young; Helen M Moore
Journal:  Biopreserv Biobank       Date:  2015-10       Impact factor: 2.300

7.  ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kwong-Kwok Wong; Arthur Gutierrez-Hartmann; Joseph Kwong; David M Gershenson; Samuel C Mok
Journal:  Oncotarget       Date:  2017-03-07

8.  New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx.

Authors:  Mohamed Mounir; Marta Lucchetta; Tiago C Silva; Catharina Olsen; Gianluca Bontempi; Xi Chen; Houtan Noushmehr; Antonio Colaprico; Elena Papaleo
Journal:  PLoS Comput Biol       Date:  2019-03-05       Impact factor: 4.475

9.  PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Authors:  Celestine S Tung; Samuel C Mok; Yvonne T M Tsang; Zhifei Zu; Huijuan Song; Jinsong Liu; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson; Kwong-Kwok Wong
Journal:  Mod Pathol       Date:  2009-06-12       Impact factor: 7.842

10.  Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure.

Authors:  Ovidiu Balacescu; Loredana Balacescu; Oana Tudoran; Nicolae Todor; Meda Rus; Rares Buiga; Sergiu Susman; Bogdan Fetica; Laura Pop; Laura Maja; Simona Visan; Claudia Ordeanu; Ioana Berindan-Neagoe; Viorica Nagy
Journal:  BMC Cancer       Date:  2014-04-08       Impact factor: 4.430

View more
  4 in total

1.  Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis.

Authors:  Kuo-Min Su; Hong-Wei Gao; Chia-Ming Chang; Kai-Hsi Lu; Mu-Hsien Yu; Yi-Hsin Lin; Li-Chun Liu; Chia-Ching Chang; Yao-Feng Li; Cheng-Chang Chang
Journal:  Biomedicines       Date:  2021-07-22

2.  PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients.

Authors:  Linan Xing; Songyu Tian; Wanqi Mi; Yongjian Zhang; Yunyan Zhang; Yuxi Zhang; Fengye Xu; Chunlong Zhang; Ge Lou
Journal:  Front Cell Dev Biol       Date:  2021-01-28

3.  Prognostic value of CDCA3 in kidney renal papillary cell carcinoma.

Authors:  Hao Li; Mi Li; Caihong Yang; Fengjing Guo; Sisi Deng; Lixi Li; Tian Ma; Jiyuan Yan; Hua Wu; Xiaojuan Li
Journal:  Aging (Albany NY)       Date:  2021-12-14       Impact factor: 5.682

4.  Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma.

Authors:  Ming-Min Jiang; Fan Zhao; Tao-Tao Lou
Journal:  Int J Gen Med       Date:  2021-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.